Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Authors:
- Thamir M. IsmailTIThamir M. Ismail
- Rachel G. CrickRCRachel G. Crick
- Min DuMDMin Du
- Uma ShivkumarUSUma Shivkumar
- Andrew CarnellACAndrew Carnell
- Roger BarracloughRBRoger Barraclough
- Guozheng WangGWGuozheng Wang
- Zhenxing ChengZCZhenxing Cheng
- Weiping YuWYWeiping Yu
- Angela Platt-HigginsAPAngela Platt-Higgins
- Gemma NixonGNGemma Nixon
- Philip S. RudlandPRPhilip S. Rudland
Open Access
- 10 July 2023
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 13 (7) , 1099
Abstract
Most patients who die of cancer do so from its metastasis to other organs. The calcium-binding protein S100A4 can induce cell migration/invasion and metastasis in experimental animals and is overexpressed in most human metastatic cancers. Here, we report that a novel inhibitor of S100A4 can specifically block its increase in cell migration in rat (IC50, 46 µM) and human (56 µM) triple negative breast cancer (TNBC) cells without affecting Western-blotted levels of S100A4. The moderately-weak S100A4-inhibitory compound, US-10113 has been chemically attached to thalidomide to stimulate the proteasomal machinery of a cell. This proteolysis targeting chimera (PROTAC) RGC specifically eliminates S100A4 in the rat (IC50, 8 nM) and human TNBC (IC50, 3.2 nM) cell lines with a near 20,000-fold increase in efficiency over US-10113 at inhibiting cell migration (IC50, 1.6 nM and 3.5 nM, respectively). Knockdown of S100A4 in human TNBC cells abolishes this effect. When PROTAC RGC is injected with mouse TNBC cells into syngeneic Balb/c mice, the incidence of experimental lung metastases or local primary tumour invasion and spontaneous lung metastasis is reduced in the 10–100 nM concentration range (Fisher’s Exact test, p ≤ 0.024). In conclusion, we have established proof of principle that destructive targeting of S100A4 provides the first realistic chemotherapeutic approach to selectively inhibiting metastasis.Keywords
Funding Information
- Cancer and Polio Research Fund, Wirral UK (BSR10021, C1440/A3019, GO801447, 1776284)
- Cancer Research UK (BSR10021, C1440/A3019, GO801447, 1776284)
- Medical Research Council UK (BSR10021, C1440/A3019, GO801447, 1776284)
- Engineering and Physical Sciences Research Council UK (BSR10021, C1440/A3019, GO801447, 1776284)
This publication has 71 references indexed in Scilit:
- S100P Dissociates Myosin IIA Filaments and Focal Adhesion Sites to Reduce Cell Adhesion and Enhance Cell MigrationJournal of Biological Chemistry, 2012
- S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cellsMolecular Biology of the Cell, 2011
- Sumoylation and Nuclear Translocation of S100A4 Regulate IL-1β-mediated Production of Matrix Metalloproteinase-13Journal of Biological Chemistry, 2010
- Significance of the Fanconi Anemia FANCD2 Protein in Sporadic and Metastatic Human Breast CancerThe American Journal of Pathology, 2010
- Phenothiazines inhibit S100A4 function by inducing protein oligomerizationProceedings of the National Academy of Sciences, 2010
- Self-association of Calcium-binding Protein S100A4 and MetastasisJournal of Biological Chemistry, 2010
- A Biosensor of S100A4 Metastasis Factor Activation: Inhibitor Screening and Cellular Activation DynamicsBiochemistry, 2007
- The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour fociInternational Journal of Experimental Pathology, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Molecular cloning and sequence of the gene for p9Ka a cultured myoepithelial cell protein with strong homology to S-100, a calcium-binding proteinJournal of Molecular Biology, 1987